Company intelligence / Profile preview

Passkey Therapeutics

Cambridge, Massachusetts, United Statespasskeytx.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Passkey Therapeutics has developed the Locksmith platform to identify novel protein combinations ("Multilogs") as therapeutic targets. The company aims to create Synergistic Multifunctional Therapeutics (SMThs) that modulate these groups with a single molecule. As of late 2024, the company has raised $20 million in seed funding and plans to advance internal programs in two therapeutic areas toward clinical trials but remains preclinical with no disclosed clinical results.

Therapeutic areas: OncologyMetabolic DisordersImmunologyNeurology
Modalities: Small moleculesbiologics (including antibodies)
Industry: Biotech

Partnerships

No major partnerships announced as of May 2025; seeking future pharma collaborations

Beyond the preview

Go deeper on Passkey Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Passkey Therapeutics.

Explore the full profile